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Abstract (196 words)
The development of vemurafenib resistance limits the long-term efficacy of this drug for treatment of metastatic melanomas with the V600E BRAF mutation. Inhibition of downstream MAPK signaling with vemurafenib induces apoptotic cell death mediated by caspase-3, suggesting that addition of a procaspase-3 activator could enhance anticancer effects. Here we show that the combination of PAC-1, a procaspase-activating compound, and vemurafenib is highly synergistic in enhancing caspase-3 activity and apoptotic cell death in melanoma cell lines harboring the V600E BRAF mutation. In vivo, the combination displays a favorable safety profile in mice, and exerts significant antitumor effects. We further demonstrate that addition of PAC-1 to the clinically useful combination of vemurafenib and a MEK inhibitor, trametinib, starkly enhances the caspase-3 activity and proapoptotic effect of the combination. Moreover, addition of low concentration PAC-1 also delays the regrowth of cells following treatment with vemurafenib. Finally, PAC-1 remains potent against vemurafenib-resistant A375VR cells in cell culture and synergizes with vemurafenib to exert antitumor effects on A375VR cell growth in vivo.
Collectively, our data suggest that inhibition of MAPK signaling combined with concurrent procaspase-3 activation is an effective strategy to enhance the antitumor activity of vemurafenib and mitigate the development of resistance.
Introduction
Melanoma is the most common cutaneous malignancy and upon metastasis is considered the deadliest form of skin cancer. (1) The discovery that approximately 50% of melanomas harbor the V600E mutation in the BRAF protein(2) spurred the development of therapies, novel and rationally-designed combination studies with other kinase inhibitors are being explored. (11, 12) Despite all efforts to date, the development of resistance to targeted V600E BRAF therapies emerges in virtually 100% of patients treated; acquired drug resistance to this class of agents remains a significant obstacle to dramatically enhanced survival benefits for metastatic melanoma patients.
In contrast to many studies that have focused on the combination of vemurafenib with inhibitors of diverse and druggable kinases, combination therapy of vemurafenib with agents that activate the apoptotic pathway have not been extensively explored. In part, this lack of exploration might be attributed to the fact that melanoma cells possess multiple defects in their apoptotic signaling pathways, (13) (14) (15) rendering them resistant to many proapoptotic stimuli. We hypothesized that a suitable proapoptotic agent that induces apoptosis downstream of these apoptotic defects would be highly synergistic with V600E BRAF inhibitors.
Given that the aberrations in the apoptotic signaling cascades in melanoma cells Here we report the synergistic activity of PAC-1+vemurafenib and PAC1+vemurafenib+trametinib in enhancement of caspase-3 activity and apoptotic cell death in 
Annexin V/PI flow cytometry analysis
70,000 cells were seeded in 12-well plates and allowed to adhere before addition of compounds. Cells were treated with compounds for 24 h at 37 o C, after which they were harvested and resuspended in 6 450 µL of cold buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 pH 7.4) premixed with Annexin V-FITC and PI (0.55 µg/mL) dyes. Samples were analyzed on a BD Biosciences LSR II flow cytometer and data analysis was performed using FCS Express V3-2.
Caspase-3/7 activity assay 5,000-8,000 cells were plated in 96 well plates and allowed to adhere. Cells were treated with 1 µM of staurosporine for 24 h or with 13 µM of raptinal (37) 
PCR and sequencing
A375 and A375VR cells were lysed and RNA extracted using the RNeasy kit (Qiagen). 900 ng of RNA was used for reverse transcription reaction using iScript cDNA synthesis kit (BioRad). qPCR reactions were ran on the 7900HT fast real-time PCR system (Applied Biosystems). Regular PCR reactions were ran using the MyFi Mix PCR kit (Bioline) for 35 cycles and ran on a 1% agarose gel. Target amplicons were gel extracted and sequenced at the UIUC core sequencing facility. Primers used can be found in the Supplementary Information.
A375 and A375VR xenograft model
All animal studies were performed in accordance with UIUC IACUC guidelines (protocol no. 14292). 0.1 mL of A375 or A375VR in 1:1 DMEM:matrigel (Corning) was injected into the right flank of 6-7 (A375) or 5 (A375VR) week old female athymic nude mice (Charles River). In the both models, the mice were randomized into four groups: control, 100 mg/kg PAC-1, 10 mg/kg vemurafenib, and the combination of 100 mg/kg PAC-1 and 10 mg/kg vemurafenib (n=8). Initial tumor volume measurements were taken and dosing was initiated for a period of 15 days. Vemurafenib was formulated as 5% DMSO in 1% methyl cellulose and given twice daily by oral gavage (p.o.). PAC-1 was formulated in 200 mg/mL hydroxypropyl-β-cyclodextrin at pH 5.5 and given by intraperitoneal (i.p.) injection. Tumor length and width measurements were taken three times a week and volume was calculated as 0.52*L*W (Fig. 1B) . The ability of the combination of PAC-1+vemurafenib to induce apoptotic cell death was then assessed in these cell lines. Under conditions (24 h incubation with compounds) where neither vemurafenib nor PAC-1 induced significant apoptotic death (≤10%) as single agents, the PAC-1+vemurafenib combination induces significant apoptosis (20-45%) in cell lines with the V600E BRAF mutation (Fig. 1C) . A similar trend was also observed when a lower concentration of vemurafenib (0.5 μM) was evaluated in combination with PAC-1 in V600E BRAF cell lines (Supplementary Fig. S1 ). However, the PAC-1+vemurafenib combination does not induce synergistic apoptosis in cell lines with wild-type BRAF (Fig. 1C) . PAC-1 and vemurafenib synergize to enhance caspase-3 activity and apoptosis in A375, SK-MEL-5 and UACC-62 cells. In order to more broadly explore the observed synergy, apoptotic death was assessed in three human V600E BRAF melanoma cell lines treated with a matrix of concentrations of PAC-1 and vemurafenib that induce minimal apoptosis as single agents. In these experiments, large increases in the populations of apoptotic cells (beyond the additive effect of single agents alone) were observed in A375 ( Fig. 2A) , SK-MEL-5 (Supplementary Fig. S2A ) and UACC-62 ( Supplementary   Fig. S3A ). To quantify the synergy of this drug combination, combination indices (CI) were calculated.
Results
The combination of PAC-1 and vemurafenib enhances apoptosis in cells with
A drug combination that is synergistic will have a CI value less than 1, while a value of 1 reflects an additive effect.(38) 93% of the calculated CI values are less than 1 (A375 in Fig. 2B , SK-MEL-5 in Supplementary Fig. S2B and UACC-62 in Supplementary Fig. S3B ), indicating synergism for the combination across all three cell lines tested.
To assess if the increase in apoptosis was a result of increased activation of executioner procaspases, caspase-3/-7 enzymatic activity was evaluated in A375 cells (after lysis) using a fluorogenic substrate.
In A375 cells treated with vemurafenib or PAC-1 alone (at the same concentrations used in Fig. 1C ), negligible increases in caspase-3 activity were observed at these time points and concentrations ( Fig.   2C) . However, when A375 cells were treated with PAC-1 and vemurafenib, a significant increase in caspase-3 activity was observed as early as 7 h post-treatment (Fig. 2C) . In Western blot analyses, neither of the single agents had an effect on PARP-1 cleavage at these time points and concentrations; however, the combination resulted in significant cleaved PARP-1 (Fig. 2D) , a result of the increased caspase-3/-7 activity in cells treated with the PAC-1+vemurafenib combination. After treatment with the combination for 24 h, near-complete cleavage of PARP-1 was observed in A375 cells (Fig. 2D) . Similar results for the caspase-3/-7 activity assay and cleavage of PARP-1 were also observed in SK-MEL-5 ( Supplementary Fig. S2C and D) and UACC-62 cells ( Supplementary Fig. S3C and D) .
The PAC-1 derivative PAC-1a (Fig. 1A) Fig. S4A-C) . This result is also consistent with the absence of increased PARP-1 cleavage in cells treated with the PAC-1a and vemurafenib combination (Supplementary Fig. S4D ), indicating that the cells did not undergo apoptotic death. Fig. S5A-C) . The lack of PAC-1+vemurafenib synergy in cell lines (Fig. 2E) . However, significant increases in the amount of cleaved PARP-1 were only observed in cells treated with both PAC-1 and vemurafenib (Fig. 2E) . Similar results were also observed in SK-MEL-5 ( Supplementary Fig. S2E ) and UACC-62 cells (Supplementary Fig. S3E ). At low concentrations of vemurafenib (0.1 and 0.25 µM), where incomplete inhibition of ERK1/2 phosphorylation was observed, slight increase in PARP-1 cleavage over that single agent effects was also observed (Fig. 2E) . This result suggests that even with incomplete inhibition of ERK1/2 phosphorylation, procaspase-3 activation, which is downstream of ERK1/2 signaling, can be enhanced with the addition of PAC-1 to vemurafenib treatments. Taken together, the data show that procaspase-3 activation via PAC-1 dramatically enhances the proapoptotic effect of vemurafenib in cell lines with V600E BRAF mutation.
Inhibition of ERK1
Addition of PAC-1 to vemurafenib and trametinib enhances caspase-3 activity and apoptosis.
Addition of a MEK1/2 inhibitor, such as trametinib, is widely used in the clinic to enhance the efficacy of vemurafenib in V600E BRAF melanomas. (8, 9) To explore the effect of PAC-1 with this combination, cells
were treated with vemurafenib+trametinib, in the presence or absence of PAC-1, and apoptosis was assessed. In both A375 and UACC-62 cell lines, vemurafenib+trametinib co-treatment led to mere additive increases in the population of apoptotic cells (Fig. 3A) . In contrast, the addition of PAC-1 led to a large increase in the population of apoptotic cells, beyond the additive effect of single agents alone (Fig. 3A) . Vemurafenib+trametinib co-treatment did not lead to PARP-1 cleavage, while addition of PAC-1 led to near quantitative cleavage of PARP-1 (Fig. 3B) . To explore if the increased apoptotic cell death in the presence of PAC-1 is a result of enhanced enzymatic activity of executioner caspases, the caspase-3/-7 activity of A375 and UACC-62 cells treated with vemurafenib+trametinib, plus or minus PAC-1, was assessed. Again, a dramatic increase in caspase-3/-7 activity was observed when PAC-1 was included, an effect that was absent without addition of PAC-1 (Fig. 3C) .
The combination of vemurafenib and PAC-1 significantly reduces tumor burden in an A375
xenograft model. To determine the antitumor effect of the PAC-1+vemurafenib combination in vivo, an A375 xenograft model(39) was used. In this model, nude mice were inoculated subcutaneously with A375 cells, and after allowing the tumors to grow, mice were randomized based upon tumor volume into four groups [F=0.03 < F critical (3.01)] and dosed with PAC-1, vemurafenib, or the combination for 15 days. Treatment with PAC-1 alone led to minimal reduction in tumor mass and volume compared to untreated control mice ( Fig. 4A and B) . Mice dosed with vemurafenib alone experienced a moderate reduction (53%; p=0.04) in tumor volume and mass compared to control ( Fig. 4A and B) , with 3 out of 8 mice having comparable tumor mass as the control mice (Fig. 4B) . In contrast, mice treated with the combination of PAC-1 and vemurafenib had significantly smaller tumor burden compared to control mice (Fig. 4A, B and Supplementary Fig. S6 ). In these mice, a 78% reduction in tumor volume was observed (Fig. 4A, p=0 (Fig. 4B) , suggesting that addition of PAC-1 enhances the antitumor effects of vemurafenib in vivo and reduces the variability in response to treatment.
Examination of procaspase-3 levels in the tumor samples by Western blot showed an appreciable and consistent reduction in the amount of procaspase-3 only in tumor samples derived from mice that received the combination treatment, versus variable responses for the other dosing groups (Fig. 4C   and D) . Using immunohistochemical staining, a significant reduction in the percentage of Ki-67 expressing cells in tumors treated with PAC-1+vemurafenib was observed (Fig. 4E) , indicating that the PAC-1+vemurafenib combination was capable of not only amplifying procaspase-3 activation, but also attenuating cell proliferation. Finally, in mice treated with PAC-1+vemurafenib, no hematological toxicities were observed (Supplementary Table 1 The E max of vemurafenib (the percent cell death induced by high concentrations of compound)(40) in A375 cells is 96.8±0.3% after 5 days (Fig. 5A) , indicating that ~3% of A375 cells are insensitive to vemurafenib. Under the same conditions, PAC-1 has an E max of 99.4±0.7% (Fig. 5A) , suggesting that PAC-1 kills A375 cells quantitatively, with very few insensitive cells. We therefore hypothesized that long term treatment with vemurafenib would lead to re-growth of cancer cells, while treatment with PAC-1 should prevent re-growth. To investigate this hypothesis, A375 and SK-MEL-5 cells were plated at low densities and treated continuously with PAC-1 (4 µM) or vemurafenib (10 µM) for up to 30 days.
In A375 and SK-MEL-5 cells treated with vemurafenib, regrowth of cells was observed in as early as 20 days (Fig. 5B) . However, in wells treated with PAC-1, no regrowth was observed even after 30 days (Fig. 5B) . Thus, consistent with the higher E max value, PAC-1 is able to quantitatively kill cells thereby preventing regrowth. Fig. S7A and B) . This result indicates that the more complete cell death induced by co-treating cells with PAC-1 and vemurafenib is effective in delaying the regrowth of A375 and UACC-62.
PAC-1 synergizes with vemurafenib in vemurafenib-resistant melanoma in vivo.
To assess if PAC-1 remains active in a cell line that has acquired resistance to vemurafenib, a vemurafenibresistant A375VR cell line was generated by growing A375 parental cell line in sequentially higher concentrations of vemurafenib (0.5 µM to 1.0 µM) for 2 months. To determine the mechanism of resistance of A375VR, genes for MEK1/2, NRAS and AKT were sequenced, but no commonly reported mutations that would confer resistance were found. (41) Vemurafenib kills the A375VR cell line with a 5-day IC 50 value of 1.5 µM, 12-fold less potent compared to the sensitivity of the parental A375 (Fig. 6A) . Moreover, the vemurafenib E max for A375VR is 79±6.3%, which is 14% lower than the parental A375 cell line. While treatment of parental A375 cells with vemurafenib (0.5 or 1 µM) for 2 h results in complete inhibition of ERK1/2 phosphorylation, this effect is not observed in A375VR, consistent with resistance of A375VR to vemurafenib and continued MAPK signaling (Fig. 6B) . In contrast, PAC-1 retains activity against A375VR with an IC 50 value of 2.4 µM (vs 1.2 μM for the parental cell line, Fig. 6C ) and a similar E max . We hypothesized that despite the inability of vemurafenib to inhibit ERK1/2 phosphorylation and MAPK signaling in the resistant A375VR cell line, the combination might retain partial capacity to exert a synergistic effect based on the PARP-1 cleavage observed for PAC-1+vemurafenib treatment, even under conditions of incomplete inhibition of ERK1/2 phosphorylation (Fig. 2E) . To investigate if PAC-1 can re-sensitize A375VR cells to vemurafenib-induced apoptosis, A375VR cells were treated with PAC-1 in combination with low concentrations of vemurafenib. This combination treatment led to an increase in the proportion of cells undergoing apoptosis (Supplementary Fig. S8A, C) , suggesting that the addition of PAC-1 can bypass the resistance mechanism of A375VR to vemurafenib. This effect was abolished when inactive variant PAC-1a was used (Supplementary Fig. S8C ). The PAC-1+vemurafenib combination was synergistic, inducing an average of 7.5% higher population of apoptotic cells than predicted by the Bliss independence model (44) (Supplementary Fig. S8A and B) . Finally, to determine if PAC-1 can synergize with vemurafenib in vivo, A375VR cells were implanted subcutaneously in nude mice, and the mice were dosed daily for 15 days with vemurafenib (10 mg/kg), PAC-1 (100 mg/kg) or the combination. Treatment with vemurafenib or PAC-1 alone does not exert any antitumor affect in this in vivo model, while treatment with combination led to significant reduction in tumor volume compared to the untreated control (Fig. 6D) .
Discussion
Given that the aberrations in the apoptotic signaling cascades in melanoma cells are upstream of the activation of procaspase-3, small molecules that directly activate procaspase-3 can induce 
apoptosis by bypassing the defective apoptotic circuitry. Activation of procaspase-3 with PAC-1 has been shown previously to have single agent efficacy against melanoma cells in culture, (21, 33, 34 ) and now we show that PAC-1+vemurafenib, or PAC-1+vemurafenib+trametinib, are powerfully synergistic in the induction of caspase-3 activity and apoptotic cell death in melanomas with V600E BRAF mutation.
Besides melanomas, the V600E BRAF mutation has been reported in several other cancers including Erdheim-Chester disease (ECD) (54%) (45) , Langerhans'-cell histiocytosis (LCH) (57%)(45), non-smallcell lung cancer (NSCLC) (1.5%)(46) and hairy-cell leukemia (100%) (47) . In two recent Phase II trials, efficacy of vemurafenib in several non-melanoma cancers harboring the V600E BRAF mutation was 
